EP0628079A1 - Peptides du virus de l'hepatite c - Google Patents

Peptides du virus de l'hepatite c

Info

Publication number
EP0628079A1
EP0628079A1 EP93904270A EP93904270A EP0628079A1 EP 0628079 A1 EP0628079 A1 EP 0628079A1 EP 93904270 A EP93904270 A EP 93904270A EP 93904270 A EP93904270 A EP 93904270A EP 0628079 A1 EP0628079 A1 EP 0628079A1
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
arg
antibody
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93904270A
Other languages
German (de)
English (en)
Inventor
Ian Pike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0628079A1 publication Critical patent/EP0628079A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to a novel peptide capable of binding to antibody specific for parenterally transmitted non A non B hepatitis (PT-NANBH) in particular (HCV) and the use of such a peptide in an im unoassay for the detection of HCV or a vaccine for its prevention.
  • PT-NANBH parenterally transmitted non A non B hepatitis
  • HCV non B hepatitis
  • Non A non B hepatitis is by definition a diagnosis of exclusion and has generally been employed to describe cases of viral hepatitis infection in human beings that are not due to hepatitis A or B viruses.
  • the PT-NANBH virus has also been referred to as Hepatitis C Virus (HCV) .
  • HCV Hepatitis C Virus
  • the cause of the infection has not been identified although, on clinical and epidemiological grounds, a number of agents have been thought to be responsible as reviewed in Shih et aJL (Prog Liver Pis. , 1986, 8 . , 433-452). In the USA alone, up to 10% of blood transfusions can . result in NANBH which makes it a significant problem.
  • GB-A-2 239 245 discloses nucleotide and polypeptide sequences of a viral agent responsible for Post Transfusional NANBH (PT-NANBH) , the core region of this viral agent responsible for PT-NANBH is disclosed within the nucleotide and peptide sequences.
  • the core region of the disclosed viral agent responsible for PT-NANBH was not analysed in GB-A-2 239 245. Substantial portions of the core region were used in reco binant polypeptides namely BHC-11 as disclosed in GB-A-2 239 245.
  • EP-A-0 445 423 discloses an assay for detecting the presence of an antibody to an HCV antigen by contacting the sample with a polypeptide containing at least one epitope of an HCV antigen. A polypeptide from the putative core region of HCV is used. Specific epitopic regions of the polypeptides are not identified.
  • HCV viral peptide having the following sequence (SEQ ID NO'-s: 1 and 2): Tyr-Leu-Leu-Pro-Arg-Arg (YLLPR )
  • the present invention also provides a DNA sequence encoding the peptide as defined above.
  • the DNA sequence may be synthetic or cloned.
  • Preferably the DNA sequence is as set forth in SEQ ID NO:l.
  • a novel synthetic peptide has also been synthesised which peptide has improved assay sensitivity and specificity, when compared to the natural peptide as disclosed above, in assays for HCV.
  • the present invention also provides a peptide of the general formula I
  • X represents Tyrosine, A ⁇ partic Acid, Gluta ic Acid, Leucine or Isoleucine
  • X 2 represents Leucine, Cysteine, Aspartic Acid or Glutamic Acid
  • X 3 represents Leucine, Valine
  • X 4 represents Proline or Methionine
  • X 5 represents Arginine, Aspartic Acid, Glutamic Acid, Proline, Cysteine, Phenylalanine, Isoleucine, Asparagine, Glutamine or Methionine;
  • X 6 represents Arginine, Aspartic Acid, Glutamic Acid, Serine or Cysteine and wherein the peptide is not of the formula Tyr-Leu-Leu-Pro- Arg-Arg (SEQ ID NO: l and 2) .
  • the present invention also provides a DNA sequence encoding the peptide of general formula I, which sequence can be readily ascertained, bearing in mind the degeneracy of the genetic code and codon usage.
  • the peptides of the present invention may be used individually, as part of a larger polypeptide and/or as a mixture of peptides with other peptides from the HCV genome, a heterologous genome or topographically related peptides.
  • the present invention also provides peptides which comprise the peptides as defined above, namely, SEQ ID NO's: 4 and 5 and SEQ ID NO's: 6 and 7.
  • the present invention also provides DNA sequences encoding the peptide as set forth above.
  • the DNA sequences are as set forth in SEQ ID NO's: 4 and 6.
  • the present invention also provides expression vectors containing the DNA sequences as herein defined, which vectors being capable, in an appropriate host, of expressing the DN sequence to produce the peptides as defined herein.
  • the expression vector normally contains control elements of DNA that effect expression of the DNA sequence in an appropriate host. These elements may vary according to the host but usually include a promoter, ribosome binding site, translational start and stop sites, and a transcriptional termination site. Examples of such vectors include plasmids and viruses.
  • Expression vectors of the present invention encompass both extrachromosomal vectors and vectors that are integrated into the host cell's chromosome.
  • the expression vector may contain the DNA sequence of the present invention optionally as a fusion linked to either the 5'- or 3'-end of the DNA sequence encoding, for example, ⁇ -galactosidase or to the 3'-end of the DNA sequence encoding, for example, the trp E gene.
  • the DNA sequence is optionally fused to the polyhedrin coding sequence.
  • the present invention also provides a host cell transformed with expression vectors as herein defined.
  • host cells of use with the present invention include prokaryotic and eukaryotic cells, such as bacterial, yeast, mammalian and insectcells. Particular examples of such cells are E.coli, S.cerevisiae, P. astoris, Chinese hamster ovary and mouse cells, and Spodoptera frucriperda and Tricoplusia ni.
  • the choice of host cell may depend on a number of factors but, if post-translational modification of the HCV viral peptide is important, then an eukaryotic host would be preferred.
  • the present invention also provides a process for preparing a peptides as defined herein which comprises isolating the DNA sequence, as herein defined, from the HCV genome, or synthesising DNA sequence encoding the peptides as defined herein, or generating a DNA sequence encoding the peptide of Formula I, inserting the DNA sequence into an expression vector such that it is capable, in an appropriate host, of being expressed, transforming an host cells with the expression vector, culturing the transformed host cells, and isolating the peptide.
  • the DNA sequence encoding the peptide may be synthesised using standard procedures (Gait, Oligonucleotide Synthesis: A Practical Approach. 1984, Oxford, IRL Press).
  • the desired DNA sequence obtained as described above may be inserted into an expression vector using known and standard techniques.
  • the expression vector is normally cut using restriction enzymes and the DNA sequence inserted using blunt- end or staggered-end ligation.
  • the cut is usually made at a restriction site in a convenient position in the expression vector such that, once inserted, the DNA sequences are under the control of the functional elements of DNA that effect its expression.
  • Transformation of an host cell may be carried out using standard techniques. Some phenotypic marker is usually employed to distinguish between the tran ⁇ formants that have successfully taken up the expression vector and those that have not. Culturing of the transformed host cell and isolation of the peptide as required may also be carried out using standard techniques.
  • the peptides of the present invention may be prepared by synthetic methods or by recombinant DNA technology.
  • the peptides are preferably synthesized using automatic synthesizers.
  • Antibody specific to a peptide of the present invention can be raised using the peptide.
  • the antibody may be polyclonal or monoclonal.
  • the antibody may be used in quality control testing of batches of the peptides; purification of a peptide or viral lysate; epitope mapping; when labelled, as a conjugate in a competitive type assay, for antibody detection; and in antigen detection assays.
  • Polyclonal antibody against a peptide of the present invention may be obtained by injecting a peptide, optionally coupled to a carrier to promote an immune response, into a mammalian host, such as a mouse, rat, sheep or rabbit, and recovering the antibody thus produced.
  • the peptide is generally administered in the form of an injectable formulation in which the peptide is admixed with a physiologically acceptable diluent.
  • Adjuvants such as Freund's complete adjuvant (FCA) or Freund's incomplete adjuvant (FIA) , may be included in the formulation.
  • FCA Freund's complete adjuvant
  • FIA Freund's incomplete adjuvant
  • FCA Freund's complete adjuvant
  • FIA Freund's incomplete adjuvant
  • the formulation is normally injected into the host over a suitable period of time, plasma samples being taken at appropriate intervals for assay for anti-HCV viral antibody. When an appropriate level of activity is obtained, the host is bled. Antibody is then extracted and purified from the blood plasma using standard procedures, for example, by protein A or ion-exchange chromatography.
  • Monoclonal .antibody against a peptide of the present invention may be obtained by fusing cells of an immortalising cell line with cells which produce antibody against the viral or topographically related peptide, and culturing the fused immortalised cell line.
  • an immortalising cell line with cells which produce antibody against the viral or topographically related peptide
  • culturing the fused immortalised cell line Typically, a non-human mammalian host, such as a mouse or rat, is inoculated with the peptide. After sufficient time has elapsed for the host to mount an antibody response, antibody producing cells, such as the splenocytes, are removed.
  • Cells of an immortalising cell line such as a mouse or rat myeloma cell line, are fused with the antibody producing cells and the resulting fusions screened to identify a cell line, such as a hybridoma, that secretes the desired monoclonal antibody.
  • the fused cell line may be cultured and the monoclonal antibody purified from the culture media in a similar manner to the purification of polyclonal antibody.
  • Diagnostic assays based upon the present invention may be used to determine the presence or absence of HCV infection. They may also be used to monitor treatment of such infection, for example in interferon therapy.
  • an assay for the diagnosis of viral infection there are basically three distinct approaches that can be adopted involving the detection of viral nucleic acid, viral antigen or viral antibody.
  • Viral nucleic acid is generally regarded as the best indicator of the presence of the virus itself and would identify materials likely to be infectious. However, the detection of nucleic acid is not usually as straightforward as the detection of antigens or antibodies since the level of target can be very low.
  • Viral antigen is used as a marker for the presence of virus and as an indicator of infectivity.
  • the amount of antigen present in a sample can be very low and difficult to detect.
  • Antibod detection is relatively straightforward because, in effect, the host immune system is amplifying the response to an infection by producing large amounts of circulating antibody. The natur of the antibody response can often be clinically useful, fo example IgM rather than IgG class antibodies are indicative o a recent infection, or the response to a particular vira antigen may be associated with clearance of the virus. Thu the exact approach adopted for the diagnosis of a vira infection depends upon the particular circumstances and th information sought. In the case of HCV, a diagnostic assay ma embody any one of these three approaches.
  • the method may comprise hybridisin viral RNA present in a test sample, or cDNA synthesised fro such viral RNA, with a DNA sequence corresponding to th nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding th peptide of formula I and screening the resulting nucleic aci hybrids to identify any HCV viral nucleic acid.
  • Th application of this method is usually restricted to a tes sample of an appropriate tissue, such as a liver* biopsy, i which the viral RNA is likely to be present at a high level
  • the DNA sequence corresponding to the nucleotide sequence o SEQ ID NO: l, 4 or 6 or encoding the peptide of Formula I ma take the form of an oligonucleotide or a cDNA sequenc sequence optionally contained within a plasmid. Screening of the nucleic acid hybrids is preferably carried out by using a labelled DNA sequence.
  • the peptide of the present invention is part of an oligonucleotide wherein the label is situated at a sufficient distance from the peptide so that binding of the peptide to the viral nucleic acid is not interfered with by virtue of the label being too close to the binding site.
  • One or more additional rounds of screening of one kind or another may be carried out to characterise further the hybrids and thus identify any HCV viral nucleic acid. The steps of hybridisation and screening are carried out in accordance with procedures known in the art.
  • the present invention also provides a test kit for the detection of HCV viral nucleic acid, which comprises
  • a labelled oligonucleotide comprising a DNA sequence corresponding to the nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding the peptide of formula I; and optionally;
  • test kit also contains a positive control sample to facilitate in the identification of viral nucleic acid.
  • the method may comprise contacting a test sample with a peptide of the present invention or a polyclonal or monoclonal antibody against the peptide and determining whether there is any antigen-antibody binding contained within the test sample.
  • a test kit may be provided comprising a peptide, as defined herein, or a polyclonal or monoclonal antibody thereto and means for determining whether there is any binding with antibody or antigen respectively contained in the test sample.
  • the test sample may be taken from any of the appropriate tissues and physiological fluids mentioned above for the detection of viral nucleic acid. If a physiological fluid is obtained, it may optionally be concentrated for any viral antigen or antibody present.
  • the peptide can be used to capture selectively antibody against HCV from solution, to label selectively the antibody already captured, or both to capture and label the antibody.
  • the peptide may be used in a variety of homogeneous assay formats in which the antibody reactive with the peptide is detected in solution with no separation of phases.
  • the types of assay in which the peptide is used to capture antibody f om solution involve immobilization of th peptide on to a solid surface. This surface should be capabl of being washed in some way.
  • suitable surfaces include polymers of various types (moulded into microtitr wells; beads; dipsticks of various types; aspiration tips; electrodes; and optical devices) , particles (for example latex; stabilized red blood cells; bacterial or fungal cells; spores; gold or other metallic or metal-containing sols; an proteinaceous colloids) with the usual size of the particl being from 0.02 to 5 microns, membranes (for example o nitrocellulose; paper; cellulose acetate; and hig porosity/high surface area membranes of an organic or inorgani material) .
  • the attachment of the peptide to the surface can be b passive adsorption from a solution of optimum composition whic may include surfactants, solvents, salts and/or chaotropes; o by active chemical bonding.
  • Active bonding may be through variety of reactive or activatible functional groups which ma be exposed on the surface (for example condensing agents active acid esters, halides and anhydrides; amino, hydroxyl, o carboxyl groups; sulphydryl groups; carbonyl groups; diazo groups; or unsaturated groups) .
  • the active bonding may be through a protein (itself attached to the surface passively or through active bonding) , such as albumin or casein, to which the viral peptide may be chemically bonded by any of a variety of methods.
  • a protein in this way may confer advantages because of isoelectric point, charge, hydrophilicity or other physico-chemical property.
  • the viral peptide may also be attached to the surface (usually but not necessarily a membrane) following electrophoretic separation of a reaction mixture, such as immuno precipitation.
  • the captured antibody After contacting (reacting) the surface bearing the peptide with a test sample, allowing time for reaction, and, where necessary, removing the excess of the sample by any of a variety of means, (such as washing, centrif gation, filtration, magnetism or capilliary action) the captured antibody is detected by any means which will give a detectable.signal.
  • this may be achieved by use of a labelled molecule or particle as described above which will react with the captured antibody (for example protein A or protein G and the like; anti-species or anti-immunoglobulin-sub-type; rheumatoid factor; or antibody to the peptide, used in a competitive or blocking fashion) , or any molecule containing an epitope contained in the peptide.
  • the captured antibody for example protein A or protein G and the like; anti-species or anti-immunoglobulin-sub-type; rheumatoid factor; or antibody to the peptide, used in a competitive or blocking fashion
  • the detectable signal may be optical or radioactive or physico-chemical and may be provided directly by labelling the molecule or particle with, for example, a dye,- radiolabel,. electroactive species, magnetically resonant species or fluorophore, or indirectly by labelling the molecule or particle with an enzyme itself capable of giving rise to a measurable change of any sort.
  • the detectable signal may be obtained using, for example, agglutination, or- through a diffraction or birefringent effect if the surface is in the form of particles.
  • Assays in which a peptide itself is used to label an already captured antibody require some form of labelling of the peptide which will allow it to be detected.
  • the labelling may be direct by chemically or passively attaching for example a radio label, magnetic resonant species, particle or enzyme label to the peptide; or indirect by attaching any form of label to a molecule which will itself react with the peptide.
  • the chemistry of bonding a label to the peptide can be directly through a moiety already present in the peptide, such as an amino group, or through an intermediate moiety, such as a maleimide group.
  • Capture of the antibody may be on any of the surfaces already mentioned by any reagent including passive or activated adsorption which will result in specific antibody or immune complexes being bound.
  • capture of the antibody could be by anti-species or anti-immunoglobulin-sub- type, by rheumatoid factor, proteins A, G and the like, or by any molecule containing an epitope contained in the peptide.
  • the labelled peptide may be used in a competitive binding fashion in which its binding to any specific molecule on any of the surfaces exemplified above is blocked by antigen in the sample. Alternatively, it may be used in a non-competitive fashion in which antigen in the sample is bound specifically or non-specifically to any of the surfaces above and is also bound to a specific bi- or poly-valent molecule (e.g. an antibody) with the remaining valencies being used to capture the labelled peptide.
  • a specific bi- or poly-valent molecule e.g. an antibody
  • the peptide and an antibody are separately labelled so that, when the antibody reacts with the recombinant peptide in free solution, the two labels interact to allow, for example, non-radiative transfer of energy captured by one label to the other label with appropriate detection of the excited second label or quenched first label (e.g. by fluorimetry, magnetic resonance or enzyme measurement) .
  • Addition of either viral peptide or antibody in a sample results in restriction of the interaction of the labelled pair and thus in a different level of signal in the detector.
  • a suitable assay format for detecting HCV antibody is the direct sandwich enzyme immunoassay (EIA) format.
  • EIA direct sandwich enzyme immunoassay
  • a peptide is coated onto microtitre wells.
  • a test sample and a peptide to which an enzyme is coupled are added simultaneously. Any HCV antibody present in the test sample binds both to the peptide coating the well and to the enzyme-coupled peptide. Typically, the same peptide are used on both sides of the sandwich. After washing, bound enzyme is detected using a specific substrate involving a colour change.
  • a test kit for use in such an EIA comprises:
  • washing solutions and/or buffers optionally, washing solutions and/or buffers.
  • IgG/IgM antibody capture ELISA wherein an antihu an antibody is coated onto microlitre wells, a test sample is added to the well. Any IgG or IgM antibody present in the test sample will then bind to the anti-human antibody.
  • a peptide of the present invention, which has been labelled, is added to the well and the peptide will bind to any IgG or IgM antibody which has resulted due to infection by HCV.
  • the IgG or IgM antibody can be visualized by virtue of the label on the peptide.
  • the peptides of the present invention may be used for the detection of HCV infection in many formats, namely as free peptides, in assays including classic ELISA, competition ELISA, membrane bound EIA and immunoprecipitation.
  • Peptide conjugates may be used in amplified assays and IgG/IgM antibody capture ELISA.
  • the peptide of the present invention may be incorporated into a vaccine formulation for inducing immunity to HCV in man.
  • the peptide may be presented in association with a pharmaceutically acceptable carrier.
  • the peptide may optionally be presented as part of an hepatitis B core fusion particle, as described in Clarke et al (Nature, 1987, 330. 381- 384) , or a polylysine based polymer, as described in Tarn (PNAS, 1988, 8J5. 5409-5413).
  • the peptide may optionally be attached to a particulate structure, such as liposomes or ISCOMS.
  • Pharmaceutically acceptable carriers include liquid media suitable for use as vehicles to introduce the peptide into a patient.
  • liquid media is saline solution.
  • the peptide may be dissolved or suspended as a solid in the carrier.
  • the vaccine formulation may also contain an adjuvant for stimulating the immune response and thereby enhancing the effect of the vaccine.
  • adjuvants include aluminium hydroxide and aluminium phosphate.
  • the vaccine formulation may contain a final concentration of peptide in the range from 0.01 to 5 mg/ml, preferably from 0.03 to 2 mg/ml.
  • the vaccine formulation may be incorporated into a sterile container, which is then sealed and stored at a low temperature, for example 4°C, or may be freeze-dried.
  • one or more doses of the vaccine formulation may be administered.
  • Eac dose may be 0.1 to 2 ml, preferably 0.2 to 1 ml.
  • a method fo inducing immunity to HCV in man comprises the administratio of an effective amount of a vaccine formulation, as hereinbefore defined.
  • the present invention also provides the use of a peptide as herein defined in the preparation of a vaccine for use in the induction of immunity to HCV in man.
  • Vaccines of the present invention may be administered by any convenient method for the administration of vaccines including oral and parenteral (e.g. intravenous, subcutaneous or intramuscular) injection.
  • the treatment may consist of a single dose of vaccine or a plurality of doses over a period of time.
  • HCV Core protein SEQ ID NO: 8 The N-terminal 97 amino acid residues of HCV Core protein SEQ ID NO: 8 was mapped with PEPSCAN analysis. This process involved the serological analysis of sequentially overlapping peptides which spanned the region of interest, to identify epitopic domains.
  • Ninety overlapping octameric peptides were synthesized on polypropylene pin supports according to the manufacturer's instructions (Cambridge Research Biochemicals) , such that each peptide overlapped with the preceding sequence by the seven N-terminal residues, and with the subsequent peptide by the seven C-terminal residues.
  • Serum or IgG purified from the serum of individuals confirmed to be seropositive for HCV were used to screen the peptides.
  • Example 2 Screening of the Peptides
  • the assay procedure followed was performed basically as described in the manufacturers instruction manual.
  • the time and temperature of the test antibody incubation differed from that prescribed, thereby decreasing the time taken for each assay.
  • Sera A total of 16 sera were assayed by PEPSCAN. These consisted of 12 sera from paid U.S. Donors which were identified as being positive for antibodies against HCV in routine screening at the site of donation. The remaining four sera were from patients diagnosed as having non-A non-B hepatitis, and which were subsequently shown to contain antibodies to HCV. Sera were screened either as the crude serum fraction, or as a caprylic acid preparation. Caprylic acid purification of IgG from the sera was performed as described by Stienbuch and Audran (1969) Arch. Biochem. Biophys. 134, 279-284.
  • the assay format involves sequentially incubating the various pins in microwell plates containing blocking, test antibody, conjugate, and substrate solutions.
  • the immune complex builds up on the pin with the enzyme labelled conjugate being immobilized on the bound anti-peptide antibody from the test serum.
  • the enzyme brings about the colour change which is used to quantify the amount of anti-peptide antibody bound.
  • Pins are immersed in 200 ⁇ l of Supercocktail (1% Ovalbu in, 1% bovine serum albumin in 0.15M phosphate buffered saline pH 7.2 + 0.1% Tween 20) and left to stand at room temperature for 1 hour.
  • Supercocktail 1% Ovalbu in, 1% bovine serum albumin in 0.15M phosphate buffered saline pH 7.2 + 0.1% Tween 20
  • Test antibody The test antibody is diluted between 1/200 (IgG) and 1/1000 (serum) in supercocktail. The pins are then stood in .this solution (175 ⁇ l/well) at 37°C for 1 hour. After this incubation the pins are washed four times in 0.15M phosphate buffered saline pH 7.2 + 0.05% Tween 20, each at room temperature for 10 minutes.
  • Substrate The substrate solution is made up fresh for each assay. To 100ml of 0.1M phosphate, 0.08M citrate buffer pH 4.0 is dissolved 50mg of 2,2 ⁇ -AZIN0-bis(3-ethylbenzthiazo- linsulphonic acid (ABTS) and 0.3 ⁇ l/ml 30% hydrogen peroxide is added. The pins are immersed in the wells containing substrate solution (150 ⁇ l/well) and incubated at room temperature in the dark. Once sufficient colour has developed the reaction is stopped by removing the pins. The plates are then read immediately in a spectrophotometric plate reader at a wavelength of 405nm. The absorbance values are then plotted against pin number. The epitopic domains are then defined as the continuous sequence of amino acids common to all positive pins in the domain i.e.
  • the epitope has the sequence Tyr-Leu-Leu-Pro- Arg-Arg (YLLPRR) (SEQ ID NO's: l and 2).
  • pins are cleaned by ultrasonication in disruption buffer (1% sodium dodecyl sulphate, 0.1% 2- mercaptoethanol in 0.1M sodium dihydrogen phosphate) heated to 60°C. Pins are sonicated for 30 minutes and then washed twice in distilled water at 60°C and once in boiling methanol. Pins can then be stored at room temperature sealed in bags containing silica gel, or can be re-used immediately for the next assay.
  • disruption buffer 1% sodium dodecyl sulphate, 0.1% 2- mercaptoethanol in 0.1M sodium dihydrogen phosphate
  • the Replacement Net Method was used to sequentially replace each of the constituent amino acid residues in the epitope with each of the other genetically encoded amino acids.
  • each replacement residue As an acceptable replacement for the parent sequence is given. Replacement residues were deemed acceptable when the signal of the new peptide was 80% of the parent sequence or greater.
  • HMP resin p- hydroxy ethylphenoxymethyl (HMP) resin by stepwise solid phase synthesis (proceeding from the carboxyl terminal residue towards the amino terminal residue) according to the general procedure set out in Applied Biosystems User Bulletin No 33, November 1990.
  • HMP resin was transferred into the reaction vessel of an Applied Biosystems Peptide Synthesizer Model 431A. ⁇ r ⁇ . carboxyl-terminal amino acid residue was coupled to the resin using the standard Applied Biosystems Fastmoc cycle, protocol. Unreacted coupling sites on the resin were then blocked by capping with benzoic anhydride.
  • the fully protected peptide-resin was transferred to a pear-shaped flask and treated with ethanedithiol (0.25 ml), thioanisole (0.5 ml), water (0.5 ml) and TFA (8.75 ml). -The mixture was stirred for 90 minutes at room temperature, then filtered through glass wool in a Pasteur pipette. The filtrate was dropped into ice-cold ether, contained in a Corex centrifuge tube, whereupon the peptide precipitated. The tube was centrifuged and the liquor aspirated to leave the peptide pellet in the tube.
  • a vaccine formulation may be prepared by conventional techniques using the following constituents in the indicated amounts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un nouveau peptide, dont la séquence est représentée par SEQ ID NO: 1 et 2, pouvant se fixer à un anticorps spécifique de la transmission parentérale d'hépatites non-A et non-B (PT-NANBH), en particulier (HCV), ainsi qu'à l'utilisation dudit peptide dans un immuno-essai servant à la détection de HCV ou dans un vaccin préventif.
EP93904270A 1992-02-28 1993-02-26 Peptides du virus de l'hepatite c Withdrawn EP0628079A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9204274 1992-02-28
GB929204274A GB9204274D0 (en) 1992-02-28 1992-02-28 Novel peptides
PCT/GB1993/000410 WO1993017111A1 (fr) 1992-02-28 1993-02-26 Peptides du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
EP0628079A1 true EP0628079A1 (fr) 1994-12-14

Family

ID=10711198

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93904270A Withdrawn EP0628079A1 (fr) 1992-02-28 1993-02-26 Peptides du virus de l'hepatite c

Country Status (10)

Country Link
EP (1) EP0628079A1 (fr)
JP (1) JPH07504562A (fr)
AU (1) AU688259B2 (fr)
CA (1) CA2131028A1 (fr)
CZ (1) CZ285834B6 (fr)
FI (1) FI943929A (fr)
GB (1) GB9204274D0 (fr)
SK (1) SK103594A3 (fr)
WO (1) WO1993017111A1 (fr)
ZA (1) ZA931299B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP0829488A4 (fr) * 1995-04-28 1999-04-07 Srl Inc Compose peptidique antigenique et methode de dosage immunologique
FR2775690B1 (fr) * 1998-03-09 2001-12-14 Bio Merieux Anticorps monoclonal et utilisations pour detecter des antigenes de la proteine core de vhc
CA2316130A1 (fr) * 1999-08-19 2001-02-19 Masanori Fukui Methode de detection ou de determination de la presence d'antigenes capsidiques de l'hepatite c et reactif de detection ou de determination pour utilisation avec cette methode

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0398748T3 (da) * 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9317111A1 *

Also Published As

Publication number Publication date
AU688259B2 (en) 1998-03-12
GB9204274D0 (en) 1992-04-08
JPH07504562A (ja) 1995-05-25
ZA931299B (en) 1993-10-13
FI943929A0 (fi) 1994-08-26
CA2131028A1 (fr) 1993-09-02
SK103594A3 (en) 1995-06-07
FI943929A (fi) 1994-08-26
CZ285834B6 (cs) 1999-11-17
AU3572593A (en) 1993-09-13
CZ206894A3 (en) 1995-03-15
WO1993017111A1 (fr) 1993-09-02

Similar Documents

Publication Publication Date Title
US6312889B1 (en) Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5683864A (en) Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6210675B1 (en) PT-NANB hepatitis polypeptides
EP0693687B1 (fr) Combinaisons d'antigènes de virus hépatite-C (HCV) pour l'utilisation dans des essais immunologiques d'anticorps d'anti-HCV
JP3895747B2 (ja) Ｃ型肝炎ウイルス４、５及び６型
US6596476B1 (en) Hepatitis C assay
US5229491A (en) Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus
EP0642666B2 (fr) Analyse de detection de l'hepatite c
AU655112B2 (en) HCV peptide antigens and method of determining HCV
CA2144435A1 (fr) Nouvel hybride ramifie et peptides agglutines efficaces dans le diagnostic et le traitement de l'hepatite non a non b
WO1993017110A2 (fr) Polypeptide de recombinaison du virus de l'hepatite c
EP0628079A1 (fr) Peptides du virus de l'hepatite c
US20020150990A1 (en) Hepatitis C virus peptides
EP0525910A1 (fr) Peptide non-A, non-B
US7166287B1 (en) Viral agent
WO1993011158A2 (fr) Peptides non-a, non-b
AU639560C (en) Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JPH04221398A (ja) 非ａ非ｂ型肝炎ウイルスに対する抗体と免疫化学反応するペプチド

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IE IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WELLCOME FOUNDATION LIMITED

17Q First examination report despatched

Effective date: 20000418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021112